Drug Trial Radar · NCT07218887
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Oct 24, 2025
Primary completion
Jan 27, 2032
Study completion Jan 27, 2032
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
Conditions
- BAG3 Mutation Associated Dilated Cardiomyopathy
Interventions
ALXN2350Drug
ALXN2350 is a gene therapy product consisting of an AAV9 capsid containing BAG3 transgene. It is administered as a single intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to Week 78
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Recruiting
Research Site
Palo Alto, California · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Cincinnati, Ohio · Recruiting
Research Site
Portland, Oregon · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Massa, Italy · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Majadahonda, Spain · Recruiting
Research Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.